Matej Oresic
Ph.D.
matej.oresic@utu.fi +358 29 450 3798 +358 46 923 3395 Tykistökatu 6 Turku |
Systems biology, exposome, bioinformatics, metabolomics, lipidomics, biophysics, systems medicine, computational biology
Professor Matej Orešič holds a PhD in biophysics from Cornell University (1999; Ithaca, NY, USA). He is professor of medicine, with specialization in systems medicine at Örebro University (Sweden) and a professor of biochemistry (metabolomics) at the University of Turku (Finland). Prof. Orešič’s main research areas include exposomics and metabolomics applications in biomedical research and systems medicine. He is particularly interested in the identification of environmental exposures (exposome) and disease processes associated with different metabolic phenotypes and the underlying mechanisms linking these processes with the development of specific disorders or their co-morbidities. Prof. Orešič also initiated the popular MZmine open-source project, which led to the development and release of popular software for metabolomics data processing. As of 2016, he was made a Lifetime Honorary Fellow of the Metabolomics Society. Professor Orešič currently serves as member of the Board of Directors of the Metabolomics Society and is one of the founders of the Nordic Metabolomics Society, previously serving as its chair of the board. In 2019, he co-chaired the 1st Gordon Research Conference on ‘Metabolomics and Human Health’ (Ventura, CA, USA). Previously, he also chaired the Keystone Symposium on Systems Biology of Lipid Metabolism (2015; Breckenridge, CO, USA). Professor Orešič currently coordinates Horizon Europe project “Inflammation in human early life: targeting impacts on life-course health – INITIALISE (https://initialise-project.eu/)”. He is also Co-Coordinator of the new Horizon Europe project “Investigation of endocrine-disrupting chemicals as contributors to progression of metabolic dysfunction-associated steatotic liver disease – EDC-MASLD (https://edc-masld.eu/)”.
Professor Orešič’s main research areas include exposomics and metabolomics applications in biomedical research and systems medicine. He is particularly interested in the identification of environmental exposures (exposome) and disease processes associated with different metabolic phenotypes and the underlying mechanisms linking these processes with the development of specific disorders or their co-morbidities. Prof. Orešič also initiated the popular MZmine open-source project, which led to the development and release of popular software for metabolomics data processing. Professor Orešič currently coordinates Horizon Europe project “Inflammation in human early life: targeting impacts on life-course health – INITIALISE (https://initialise-project.eu/)”. He is also Co-Coordinator of the new Horizon Europe project “Investigation of endocrine-disrupting chemicals as contributors to progression of metabolic dysfunction-associated steatotic liver disease – EDC-MASLD (https://edc-masld.eu/)”.
- Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis (2016)
- Translational Psychiatry
- The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes (vol 17, pg 260, 2015) (2016)
- Cell Host and Microbe
- The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans (2016)
- Journal of Hepatology
- Altered lipid metabolism preceding onset of islet autoimmunity and type 1 diabetes (2015)
- Diabetologia
- Analytical Lipidomics in Metabolic and Clinical Research (2015)
- Trends in Endocrinology and Metabolism
- Bioactive lipids dissociate steatosis and insulin resistance in the human liver in non-alcoholic fatty liver disease (2015)
- Diabetologia
- Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2 (2015)
- Journal of Hepatology
- COordination of Standards in MetabOlomicS (COSMOS): facilitating integrated metabolomics data access (2015)
- Metabolomics
- Erratum to: Coordination of Standards in MetabOlomicS (COSMOS): facilitating integrated metabolomics data access (vol 11, pg 1587, 2015) (2015)
- Metabolomics
- Increased Dihydroceramide/Ceramide Ratio Mediated by Defective Expression of degs1 Impairs Adipocyte Differentiation and Function (2015)
- Diabetes
- Optimizing the lipidomics workflow for clinical studies-practical considerations (2015)
- Analytical and Bioanalytical Chemistry
- Roux-en-Y Gastric Bypass Surgery Induces Early Plasma Metabolomic and Lipidomic Alterations in Humans Associated with Diabetes Remission (2015)
- PLoS ONE
- Self-organization and missing values in SOM and GTM (2015)
- Neurocomputing
- Serum Lipid and Serum Metabolite Components in relation to anthropometric parameters in EPIC-Potsdam participants (2015)
- Metabolism
- The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes (2015)
- Cell Host and Microbe
- The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity (2015)
- British Journal of Clinical Pharmacology
- The influence of sample collection methodology and sample preprocessing on the blood metabolic profile (2015)
- Bioanalysis
- The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy (2015)
- PLoS ONE
- Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity (2014)
- Diabetes
- Systems biology strategies to study lipidomes in health and disease (2014)
- Progress in Lipid Research



